Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | SMPD1 | P17405 | 4/20 | 0.50 |
| ▸ | CNR2 | P34972 | 2/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.50 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9167382 | 1.00 | PLA2G2A (0.58) | PLA2G2ALMNAHPGDMEN1KMT2A | |
| SCHEMBL9323897 | 0.96 | PLA2G2A (0.54) | PLA2G2ALMNAHPGDMEN1KMT2A | |
| SCHEMBL9324877 | 0.96 | PLA2G2A (0.54) | PLA2G2ALMNAHPGDMEN1KMT2A | |
| SCHEMBL9325186 | 0.96 | PLA2G2A (0.54) | PLA2G2ALMNAHPGDMEN1KMT2A | |
| SCHEMBL9327294 | 0.95 | NR4A2 (0.55) | PLA2G2ALMNAHPGDMEN1KMT2A | |
| SCHEMBL2650902 | 0.91 | LMNA (0.60) | LMNAHPGDMEN1KMT2ASMPD1 | |
| SCHEMBL9327299 | 0.89 | SMPD1 (0.48) | PLA2G2ALMNAHPGDSMPD1NR4A2 | |
| SCHEMBL9323928 | 0.88 | LMNA (0.60) | LMNAHPGDMEN1KMT2ANR4A2 | |
| SCHEMBL9167771 | 0.88 | PLA2G2A (0.76) | PLA2G2AMEN1KMT2ANR4A2 | |
| SCHEMBL391547 | 0.88 | MEN1 (0.71) | LMNAHPGDMEN1KMT2ASMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240252677-A1 | ONE-COMPONENT DELIVERY SYSTEM FOR NUCLEIC ACIDS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2024-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240252677-A1 | ONE-COMPONENT DELIVERY SYSTEM FOR NUCLEIC ACIDS | TLR3, TLR9, ADAR | PLA2G2A 930/4885LMNA 2652/4885HPGD 4615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.